Compare · regulatory status only

Retatrutide vs semaglutide: legal status compared

The short answer

They are restricted for opposite reasons. Semaglutide is an approved drug (Ozempic, Wegovy) whose compounded copies lost their legal basis when the shortage ended in 2025. Retatrutide has never been approved anywhere - it is Eli Lilly's investigational triple agonist, still in the regulatory pipeline with a BLA expected in early 2027 - so no legal commercial product exists at all, compounding was never permitted, and everything sold today is gray market. For athletes the difference is sharpest: semaglutide is monitored but allowed; retatrutide is prohibited outright.

Status comparison, not advice - Peptlas compares legality and oversight, never effects. Published Aug 27, 2026 (ET) · sources below

Side by side

Retatrutide vs semaglutide: legal status compared
RetatrutideSemaglutide (compounded)
ApprovalNone, anywhere - investigational (BLA to FDA expected Q1 2027)FDA-approved as Ozempic and Wegovy
Legal way to obtainNone outside clinical trials and Lilly's early-access programPrescription for the approved drugs
CompoundingNever permitted - no approval, never on the shortage list, not an eligible bulk substanceWas permitted during the shortage; routine copies ended Apr-May 2025; narrow exception remains
What is on the gray marketEverything sold is unapproved 'research' product - FDA has warned sellers, including ones using coded namesUnapproved 'research' vials exist alongside the approved drug; FDA flags salt-form products
Sport (WADA)Prohibited at all times - S0 catch-all for non-approved substancesNot prohibited - Monitoring Program since 2024
What changes nextApproval decision after the expected Q1 2027 BLAPending 503B exclusion decision

Why 'restricted' means two different things here

Peptlas marks both compounds restricted, and the badge hides an instructive asymmetry. Semaglutide's restriction is about copies of an approved drug: the molecule itself is fully legal in its branded form, and the fight is over who may manufacture it. Retatrutide's restriction is about a drug that does not legally exist yet: until the FDA (or another regulator) approves it, there is no lawful product to buy, copy, or compound - which is why the FDA's enforcement against retatrutide sellers targets the products' very existence on the market, not just their marketing claims. The full records: retatrutide and compounded semaglutide.

The sport contrast makes the asymmetry concrete: WADA does not prohibit semaglutide (it is merely monitored), but retatrutide is banned at all times under the S0 catch-all - not because of what it does, but because nothing unapproved for human use is allowed in tested sport. Same logic as the research-use-only story: approval status, not chemistry, is what the rules read.

Asked and answered

Is retatrutide legal like semaglutide is?
No. Semaglutide is an FDA-approved drug available by prescription as Ozempic or Wegovy. Retatrutide is not approved anywhere - it is investigational, with an FDA application expected in early 2027 - so there is no legal commercial retatrutide product; everything sold today is unapproved gray-market product.
Can retatrutide be compounded the way semaglutide was?
No. Compounded semaglutide was permitted only because the approved drug was in declared shortage. Retatrutide has no approved drug, was never on the shortage list, and is not an eligible bulk substance - the FDA states plainly it cannot be used in compounding.
Which one is banned for athletes?
Retatrutide - prohibited at all times under WADA's S0 category for non-approved substances. Semaglutide is not prohibited; it sits on the WADA Monitoring Program.

Sources